INVO Fertility, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2025 Annual Meeting of Stockholders held by INVO Fertility, Inc. on June 25, 2025. The meeting was conducted to vote on director elections, auditor ratification, and several capital structure proposals. A total of 842,876 shares were represented, constituting a quorum.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, or liquidity metrics. The only financial figure disclosed relates to a specific debt instrument: a 7.0% Senior Secured Convertible Debenture with a principal balance of $4,803,175 due February 11, 2026.
Material Changes and Voting Results
Stockholders approved several key proposals, while one proposal was adjourned:
- Director Elections (Proposal 1): All five nominees (Trent Davis, Rebecca Messina, Barbara Ryan, Steven Shum, Matthew Szot) were elected. Broker non-votes totaled 504,158 shares for each nominee.
- Auditor Ratification (Proposal 2): Stockholders approved the appointment of M&K CPAs PLLC as independent public accountant for the fiscal year ending December 31, 2025.
- Series C-2 Preferred Conversion (Proposal 4): Approved the issuance of common stock upon conversion of Series C-2 Non-Voting Convertible Preferred Stock. Significant opposition was recorded with 114,060 votes against.
- Debenture Conversion (Proposal 5): Approved the issuance of common stock upon conversion of the $4,803,175 Senior Secured Convertible Debenture. Significant opposition was recorded with 113,405 votes against.
- Inducement Warrant Exercise (Proposal 6): Approved the issuance of common stock upon exercise of warrants issued under an April 30, 2025 inducement letter agreement. Significant opposition was recorded with 112,942 votes against.
- Stock Incentive Plan Amendment (Proposal 7): Approved increasing the number of shares available for issuance under the 2019 Stock Incentive Plan to 1,200,000 shares (approximately 10% of fully-diluted outstanding stock).
- Say on Pay (Proposal 8): Approved the non-binding advisory resolution on executive compensation. Significant opposition was recorded with 117,286 votes against.
Outlook, Risks, and Contingencies
Adjourned Proposal: Proposal 3, regarding the amendment to the Amended and Restated Articles of Incorporation to increase authorized common shares from 4,166,666 to 50,000,000, was not approved at the initial meeting. The meeting was adjourned to July 9, 2025, at 12:00 pm Eastern Time to further solicit votes. The adjourned meeting will be held virtually.
Voting Risks: Proposals 4 through 8, which involve significant equity issuance (conversions of preferred stock, debentures, and warrants, plus plan amendments), faced substantial opposition, with "Against" votes ranging from approximately 112,000 to 117,000 shares. Additionally, broker non-votes of 504,158 shares were recorded for all proposals except the auditor ratification.
Investor Verification Checklist
- Verify the outcome of the adjourned meeting on July 9, 2025, regarding the increase in authorized shares (Proposal 3).
- Review the dilution impact of the approved conversions of the $4.8M debenture, Series C-2 Preferred Stock, and Inducement Warrants.
- Assess the implications of the high number of "Against" votes on capital structure proposals for future shareholder relations.
- Confirm the final share count and fully-diluted capitalization following the implementation of the approved Stock Incentive Plan amendment.